Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter Henry Milner is active.

Publication


Featured researches published by Peter Henry Milner.


Bioorganic & Medicinal Chemistry Letters | 2002

The antimicrobial natural product chuangxinmycin and some synthetic analogues are potent and selective inhibitors of bacterial tryptophanyl tRNA synthetase.

Murray J.B. Brown; Paul S. Carter; Ashley E. Fenwick; Andrew Fosberry; Dieter Hamprecht; Martin Hibbs; Richard L. Jarvest; Lucy Mensah; Peter Henry Milner; Peter J. O'Hanlon; Andrew J. Pope; Christine M. Richardson; Andrew West; David R. Witty

The antimicrobial natural product chuangxinmycin has been found to be a potent and selective inhibitor of bacterial tryptophanyl tRNA synthetase (WRS). A number of analogues have been synthesised. The interaction with WRS appears to be highly constrained, as only sterically smaller analogues afforded significant inhibition. The only analogue to show inhibition comparable to chuangxinmycin also had antibacterial activity. WRS inhibition may contribute to the antibacterial action of chuangxinmycin.


Bioorganic & Medicinal Chemistry Letters | 2008

Bace-1 Inhibitors Part 3: Identification of Hydroxy Ethylamines (Heas) with Nanomolar Potency in Cells.

Paul John Beswick; Nicolas Charrier; B Clarke; Emmanuel Demont; Colin Dingwall; Rachel Dunsdon; Faller A; Robert J. Gleave; Julie Hawkins; Ishrut Hussain; Christopher Norbert Johnson; David Timothy Macpherson; Graham Maile; Rosalie Matico; Peter Henry Milner; Julie Mosley; Antoinette Naylor; A O'Brien; Sally Redshaw; Riddell D; Paul Rowland; John Skidmore; Soleil; Kathrine J. Smith; Steven James Stanway; Geoffrey Stemp; A Stuart; Sharon Sweitzer; P Theobald; David Vesey

This article is focusing on further optimization of previously described hydroxy ethylamine (HEA) BACE-1 inhibitors obtained from a focused library with the support of X-ray crystallography. Optimization of the non-prime side of our inhibitors and introduction of a 6-membered sultam substituent binding to Asn-294 as well as a fluorine in the C-2 position led to derivatives with nanomolar potency in cell-based assays.


Bioorganic & Medicinal Chemistry Letters | 2008

BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs).

B Clarke; Emmanuel Demont; Colin Dingwall; Rachel Dunsdon; Faller A; Julie Hawkins; Ishrut Hussain; David Timothy Macpherson; Graham Maile; Rosalie Matico; Peter Henry Milner; Julie Mosley; Antoinette Naylor; A O'Brien; Sally Redshaw; Riddell D; Paul Rowland; Soleil; Kathrine J. Smith; Steven James Stanway; Geoffrey Stemp; Sharon Sweitzer; P Theobald; David Vesey; Daryl Simon Walter; Jon R. Ward; Gareth Wayne

Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimers disease. Herein, is described the lead generation effort which resulted, with the support of X-ray crystallography, in the discovery of potent inhibitors based on a hydroxy ethylamine (HEA) transition-state mimetic. These inhibitors were capable of lowering amyloid production in a cell-based assay.


Bioorganic & Medicinal Chemistry Letters | 2008

Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists

Giancarlo Trani; Stuart M. Baddeley; Michael A. Briggs; Tsu T. Chuang; Nigel J. Deeks; Christopher Norbert Johnson; Abir A. Khazragi; Tania L. Mead; Andrew D. Medhurst; Peter Henry Milner; Leann P. Quinn; Alison M. Ray; Dean Andrew Rivers; Tania O. Stean; Geoffrey Stemp; Brenda K. Trail; David R. Witty

Starting from a benzazepine sulfonamide 5-HT(6) receptor antagonist lead with limited brain penetration, application of a strategy of conformational constraint and reduction of hydrogen bond donor count led to a novel series of tricyclic derivatives with high 5-HT(6) receptor affinity and excellent brain:blood ratios.


Bioorganic & Medicinal Chemistry Letters | 1994

Synthesis and β-lactamase inhibition of anacardic acids and their analogues

Nicholas W. Hird; Peter Henry Milner

Abstract Several anacardic acids and their analogues were symthesised and their β-lactamase inhibitory activities were determined. The structure-activity relationships suggested by these data are discussed.


Archive | 2003

Hydroxyethylamine derivatives for the treatment of Alzheimer's disease

Emmanuel Hubert Demont; Andrew Faller; David Timothy Macpherson; Peter Henry Milner; Alan Naylor; Sally Redshaw; Steven James Stanway; David Vesey; Daryl Simon Walter


Bioorganic & Medicinal Chemistry Letters | 2008

Bace-1 Inhibitors Part 2: Identification of Hydroxy Ethylamines (Heas) with Reduced Peptidic Character.

B Clarke; Emmanuel Demont; Colin Dingwall; Rachel Dunsdon; Faller A; Julie Hawkins; Ishrut Hussain; David Timothy Macpherson; Graham Maile; Rosalie Matico; Peter Henry Milner; Julie Mosley; Antoinette Naylor; A O'Brien; Sally Redshaw; Riddell D; Paul Rowland; Soleil; Kathrine J. Smith; Steven James Stanway; Geoffrey Stemp; Sharon Sweitzer; P Theobald; David Vesey; Daryl Simon Walter; Jon R. Ward; Gareth Wayne


Archive | 2002

Benzamide derivatives, processes for their preparation, and their pharmaceutical use

Andrew Faller; David Timothy Macpherson; Peter Henry Milner; Steven James Stanway; Leontine Saskia Trouw


Journal of Organic Chemistry | 2008

Regioselective Synthesis of N-Aminoisoindolones and Mono-N- and Di-N,N′-substituted Phthalazones Utilizing Hydrazine Nucleophiles in a Palladium-Catalyzed Three-Component Cascade Process

Ronald Grigg; Visuvanathar Sridharan; Mufakhrul Shah; Simon P. Mutton; Colin A. Kilner; David Timothy Macpherson; Peter Henry Milner


Bioorganic & Medicinal Chemistry Letters | 1999

Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.

Stuart Bailey; Brian Bolognese; Andrew Faller; Pearl Louis-Flamberg; David Timothy Macpherson; Ruth J. Mayer; Lisa A. Marshall; Peter Henry Milner; Jayshree Mistry; David Glynn Smith; John G. Ward

Collaboration


Dive into the Peter Henry Milner's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge